|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
Rapid Publication |
Loss of the Antiangiogenic Pigment Epithelium-Derived Factor in Patients With Angiogenic Eye Disease
1 University Hospital Benjamin Franklin, Free University of Berlin, Department of Endocrinology, Diabetes and Nutrition, Berlin
2 German Institute of Human Nutrition Potsdam, Department of Clinical Nutrition, Bergholz-Rehbrücke, Germany
3 Lankenau Institute for Medical Research, Wynnewood, Pennsylvania
4 Department of Internal Medicine, University Hospital Mannheim, Mannheim, Germany
5 Department of Optometry and Vision Sciences, Cardiff University, Cardiff, U.K.
Retinal neovascularization characterizes proliferative diabetic retinopathy (PDR). Pigment epithelium-derived factor (PEDF) has been shown to be a major antiangiogenic growth factor in the mammalian eye. PEDF expression is suppressed by hypoxia, and changes in PEDF have been correlated to the development of retinal neovascularization in animal models of hypoxic eye disease. However, whether this concept of a reduced angiogenesis inhibitor holds true in humans is as yet unclear. In this study, we analyzed the in vivo regulation of PEDF in patients with and without hypoxic eye disease. We used immunoblots to measure PEDF in ocular fluids obtained from 64 nondiabetic and diabetic patients. In addition, immunohistochemistry of PEDF was carried out in specimens of normal human retinas and retinas with various degrees of diabetic retinopathy. The PEDF concentrations in patients with PDR (P < 0.001) or extensive nondiabetic retinal neovascularization caused by retinal-vein occlusion (P < 0.001) were lower than in control patients. Levels of PEDF were replenished in PDR patients with previous retinal scatter photocoagulation compared with PDR patients without previous photocoagulation (P = 0.01). Immunohistochemistry revealed an interstitial staining pattern as expected for a secreted protein, with an intense staining in retinas of patients without proliferative eye disease. However, in patients with PDR, little or no staining was detectable. Our data strongly support the concept that retinal angiogenesis is induced by loss of the major angiogenesis inhibitor in the eye, PEDF, in combination with an increased expression of angiogenic growth factors such as vascular endothelial growth factor. Our findings suggest that substitution of angiogenesis inhibitors may be an effective approach in the treatment of PDR.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. M Abu El-Asrar, L. Missotten, and K. Geboes Expression of hypoxia-inducible factor-1{alpha} and the protein products of its target genes in diabetic fibrovascular epiretinal membranes Br. J. Ophthalmol., June 1, 2007; 91(6): 822 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ogata, M. Matsuoka, K. Matsuyama, C. Shima, A. Tajika, T. Nishiyama, M. Wada, N. Jo, A. Higuchi, K. Minamino, et al. Plasma Concentration of Pigment Epithelium-Derived Factor in Patients with Diabetic Retinopathy J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1176 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Wang, S. X. Zhang, R. Mott, R. R. Knapp, W. Cao, K. Lau, and J.-x. Ma Salutary Effect of Pigment Epithelium-Derived Factor in Diabetic Nephropathy: Evidence for Antifibrogenic Activities Diabetes, June 1, 2006; 55(6): 1678 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cai, C. Parr, G. Watkins, W. G. Jiang, and M. Boulton Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin. Cancer Res., June 1, 2006; 12(11): 3510 - 3517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Amaral, R. N. Fariss, M. M. Campos, W. G. Robison Jr, H. Kim, R. Lutz, and S. P. Becerra Transscleral-RPE Permeability of PEDF and Ovalbumin Proteins: Implications for Subconjunctival Protein Delivery Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4383 - 4392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Notari, A. Miller, A. Martinez, J. Amaral, M. Ju, G. Robinson, L. E. H. Smith, and S. P. Becerra Pigment Epithelium-Derived Factor Is a Substrate for Matrix Metalloproteinase Type 2 and Type 9: Implications for Downregulation in Hypoxia Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2736 - 2747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Maar, A. Luksch, A. Graebe, E. Ergun, B. Wimpissinger, M. Tittl, P. Vecsei, M. Stur, and L. Schmetterer Effect of Laser Photocoagulation on the Retinal Vessel Diameter in Branch and Macular Vein Occlusion Arch Ophthalmol, July 1, 2004; 122(7): 987 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Shao, J. Sima, S. X. Zhang, J. Jin, P. Reinach, Z. Wang, and J.-x. Ma Suppression of Corneal Neovascularization by PEDF Release from Human Amniotic Membranes Invest. Ophthalmol. Vis. Sci., June 1, 2004; 45(6): 1758 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Canton, E. M. Martinez-Caceres, C. Hernandez, C. Espejo, J. Garcia-Arumi, and R. Simo CD4-CD8 and CD28 Expression in T Cells Infiltrating the Vitreous Fluid in Patients With Proliferative Diabetic Retinopathy: A Flow Cytometric Analysis Arch Ophthalmol, May 1, 2004; 122(5): 743 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Liu, J.-G. Ren, W. L. Cooper, C. E. Hawkins, M. R. Cowan, and P. Y. Tong Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site PNAS, April 27, 2004; 101(17): 6605 - 6610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Abe, T. Shimizu, S.-i. Yamagishi, A. Shibaki, S. Amano, Y. Inagaki, H. Watanabe, H. Sugawara, H. Nakamura, M. Takeuchi, et al. Overexpression of Pigment Epithelium-Derived Factor Decreases Angiogenesis and Inhibits the Growth of Human Malignant Melanoma Cells in Vivo Am. J. Pathol., April 1, 2004; 164(4): 1225 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Funatsu, H. Yamashita, H. Noma, H. Mochizuki, T. Mimura, T. Ikeda, and S. Hori Outcome of Vitreous Surgery and the Balance between Vascular Endothelial Growth Factor and Endostatin Invest. Ophthalmol. Vis. Sci., March 1, 2003; 44(3): 1042 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Simo, A. Lecube, L. Sararols, J. Garcia-Arumi, R. M. Segura, R. Casamitjana, and C. Hernandez Deficit of Somatostatin-Like Immunoreactivity in the Vitreous Fluid of Diabetic Patients: Possible role in the development of proliferative diabetic retinopathy Diabetes Care, December 1, 2002; 25(12): 2282 - 2286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Noma, H. Funatsu, H. Yamashita, S. Kitano, H. K. Mishima, and S. Hori Regulation of Angiogenesis in Diabetic Retinopathy: Possible Balance Between Vascular Endothelial Growth Factor and Endostatin Arch Ophthalmol, August 1, 2002; 120(8): 1075 - 1080. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |